Using a neuroprotective drug to treat patients who have a serious type of brain bleeding caused by a rupture of a weakened blood vessel (aneurysm)

Cerebrolysin as add-on therapy in patients with high Hunt-Hess grade subarachnoidal hemorrhage

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN16818128

Enrollment

Registered

2023-07-10

Start date

2021-09-01

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroprotection in patients with severe aneurysmal subarachnoidal haemorhage after endovascular treatment of ruptured aneurysm Circulatory System

Interventions

Patients with aneurysmal SAH and initial Hunt-Hess grade of 3 and more and secured aneurysm by endovascular approach will be included in the study and routinely treated during hospital stay. All patie

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aneurysmal subarachnoidal haemorrhage 2. Inital Hunt-Hess grade 3 or higher 3. Endovasculary secured aneurysm 4. Availability to add-on treatment not more than 24 hours after embolisation

Exclusion criteria

Exclusion criteria: 1. Known allergy to Cerebrolysine 2. Refusal of participation in the study

Design outcomes

Primary

Measure	Time frame
Functional outcome of the patients measured with mRS 90 days after the bleeding	—

Secondary

Measure	Time frame
1. Development of delayed neurological deficit during 21 days after the bleeding, verified by neuroimaging 2. Developement of the vasospasms during 14 days after the bleeding during TCD monitoring 3. Mortality after 90 days measured using patient records 4. Safety of Cerebrolysine (adverse events) up to end of study	—

Countries

Croatia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026